Long-term treatment of obese & overwt patients, including patients w/ risk factors associated w/ obesity, in conjunction w/ a mildly hypocaloric diet. Treatment results in an improvement of risk factors & comorbidities associated w/ obesity, including hypercholesterolemia, NIDDM, impaired glucose tolerance, hyperinsulinemia, HTN & a reduction of visceral fat. Provides additional glycaemic control in combination w/ antidiabetic agents eg, metformin, sulfonylurea &/or insulin in type 2 diabetic patients who are overwt (BMI >28 kg/m2
) or obese (BMI >30 kg/m2
), in conjunction w/ a mildly hypocaloric diet.